Vancomycin and meropenem in acrylic cement: Elution kinetics of in vitro bactericidal action

Andollina, Agnese; Bertoni, G.; Zolezzi, Carola; Trentani, F; Trentani, P; Borrelli, Anna; Tigani, Domenico

doi:10.1007/s12306-008-0048-1

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[40][41][42][43] PMMA is a hydrophobic polymer; therefore, only a small percentage of the encapsulated drug is released from monolithic forms with low surface area to volume ratios. [44][45][46][47][48] The release profiles may be modulated by the inclusion of water-soluble excipients 49 or increasing the surface area by using electrospinning. 50 The ideal electrospinning parameters, to create defect-free, continuous NFs, were set at PMMA/PEG mass ratio 5 9/1, voltage 5 24 kV, syringe pump rate 5 1 mL/h, and a needle to collector gap of 20 cm.…”

Section: Fiber Formation and Characterizationmentioning

confidence: 99%

Development of a nanofibrous wound dressing with an antifibrogenic properties in vitro and in vivo model

Poormasjedi‐Meibod

Pakyari

Jackson

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

Dermal fibrosis, characterized by excessive extracellular matrix (ECM), is a pathological condition with limited effective therapeutic modalities. Lack of an antiscarring dressing further impedes the preventive measures for this condition. Here, we develop a new antiscarring dressing and investigate its potential as a slow-releasing vehicle for kynurenic acid (KynA), an antifibrotic agent. KynA was incorporated into polymethyl methacrylate (PMMA) nanofibers, containing increasing concentration of polyethylene glycol (PEG). Fibre morphology, water absorption capacity, surface hydrophilicity, in vitro drug release profile, and in vivo antifibrotic effects were investigated. Increasing concentrations of PEG (1-20%) significantly increased surface hydrophilicity, water absorption capacity, and drug release. Based on the obtained release profiles, PMMA + 10% PEG was the preferred formulation for sustained KynA release up to 120 hours. In vitro studies confirmed the preservation of KynA antifibrotic properties during electrospinning, indicated by fibroblasts proliferation suppression and ECM expression modulation. In vivo application of KynA-incorporated films significantly inhibited collagen (23.89 ± 4.79 vs. 6.99 ± 0.41, collagen-I/β-actin mRNA expression, control vs. treated) and fibronectin expression (7.18 ± 1.09 vs. 2.31 ± 0.05, fibronectin/β-actin mRNA expression, control vs. treated) and enhanced the production of an ECM-degrading enzyme (2.03 ± 0.88 vs. 11.88 ± 1.16 MMP-1/β-actin mRNA expression, control vs. treated). The fabricated KynA-incorporated films can be exploited as antifibrotic wound dressings. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 2334-2344, 2016.

show abstract

Section: Fiber Formation and Characterizationmentioning

confidence: 99%

Development of a nanofibrous wound dressing with an antifibrogenic properties in vitro and in vivo model

Poormasjedi‐Meibod

Pakyari

Jackson

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…Baleani et al [3] found that 0.5 g of meropenem with 0.5 g of vancomycin in 40 g cement was mechanically acceptable. This became unacceptable when the vancomycin dose was increased to 1 g. Andollina et al [1] conducted an in vitro study with antibiotic-impregnated cement exposed to colonies of bacteria. They showed that 1 g of both vancomycin and meropenem were needed to eliminate pseudomonas.…”

Section: Antibiotic Use In Spacersmentioning

confidence: 99%